Fusion of dendritic cells and CD34+CD38- acute myeloid leukemia (AML) cells potentiates targeting AML-initiating cells by specific CTL induction

Journal of Immunotherapy

Volumn 32, Issue 4, 2009, Pages 408-414

  Lei, Zhang ^a   Zhang, Gui Mei ^a   Hong, Mei ^b   Feng, Zuo Hua ^a   Huang, Bo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

AML initiating cells; CTLs; Dendritic cells; Fusion; Leukemia progenitor cells; Specific killing

Indexed keywords

CD34 ANTIBODY; CD38 ANTIGEN; CD34 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CELL FUSION; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; STEM CELL; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE;

ADULT; ANIMALS; ANTIGENS, CD34; ANTIGENS, CD38; CELL FUSION; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC;

EID: 67449092222     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181a01abb     Document Type: Article

References (27)

1. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood. 2003;101:3142-3149.
2. - cells in acute myeloid leukemia. Clin Cancer Res. 2005;11:2436-2444.
3. Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res. 2006; 12:340-344.
4. Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med. 1999;50:369-386.
5. Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol Immunother. 2006;55:329-338.
6. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003;63: 2127-2133.
7. Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106:4086-4092.
8. Dybkaer K, Pedersen B, Skou Pedersen F, et al. Identification of acute myeloid leukemia patients with diminished expression of CD13 myeloid transcripts by competitive reverse transcription polymerase chain reaction (RT-PCR). Leuk Res. 2000;24: 497-506.
9. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558-561.
10. Wang J, Saffold S, Cao X, et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol. 1998;161: 5516-5524.
11. Xia J, Tanaka Y, Koido S, et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol. 2003; 170:1980-1986.
12. Avigan D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res. 2004;10:6347S-6352S.
13. Liu Y, Zhang W, Chan T, et al. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res. 2002;26:757-763.
14. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
15. Ailles LE, Gerhard B, Kawagoe H, et al. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood. 1999;94:1761-1772.
16. Yasuda T, Kamigaki T, Kawasaki K, et al. Superior antitumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother. 2007;56:1025-1036.
17. Sperr WR, Florian S, Hauswirth AW, et al. CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. Leuk Lymphoma. 2005;46:1115-1120.
18. Parcells BW, Ikeda AK, Simms-Waldrip T, et al. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells. 2006;24:1174-1184.
19. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med. 2006;12:296-300.
20. Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells. 2006;24:2603-2610.
21. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005; 15:494-501.
22. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. C A Cancer J Clin. 2002;52:363-371.
23. Chan WI, Huntly BJ. Leukemia stem cells in acute myeloid leukemia. Semin Oncol. 2008;35:326-335.
24. Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol Med. 2007;13:470-481.
25. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63: 5821-5828.
26. Shmelkov SV, St Clair R, Lyden D, et al. AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 2005;37:715-719.
27. Mehra N, Penning M, Maas J, et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res. 2006; 12:4859-4866.